Interference with pre-B-cell receptor signaling offers a therapeutic option for TCF3-rearranged childhood acute lymphoblastic leukemia

Blood Cancer Journal

Volumn 4, Issue 2, 2014, Pages

  Van Der Veer, A ^a   Van Der Velden, V H J ^b   Willemse, M E ^a   Hoogeveen, P G ^b   Petricoin, E F ^c   Beverloo, H B ^b   Escherich, G ^d   Horstmann, M A ^d   Pieters, R ^a,e   Den Boer, M L ^a,e  

^a SOPHIA CHILDREN S HOSPITAL   (Netherlands)

^b ERASMUS MEDICAL CENTER   (Netherlands)

^c GEORGE MASON UNIVERSITY   (United States)

^d UNIVERSITY MEDICAL CENTER HAMBURG EPPENDORF   (Germany)

^e DUTCH CHILDHOOD ONCOLOGY GROUP   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

BIOLOGICAL MARKER; BRUTON TYROSINE KINASE; IBRUTINIB; IMMUNOGLOBULIN HEAVY CHAIN; IMMUNOGLOBULIN LIGHT CHAIN; INTERFERON REGULATORY FACTOR 4; PHOSPHATIDYLINOSITOL 3 KINASE P110 DELTA; PLC GAMMA 2 PROTEIN; PRE B CELL RECEPTOR; PROTEIN KINASE LYN; PROTEIN KINASE SYK; PROTEIN KINASE ZAP 70; SLP65 PROTEIN; TRANSCRIPTION FACTOR 7 LIKE 1; UNCLASSIFIED DRUG;

ACUTE LYMPHOBLASTIC LEUKEMIA; CELL LYSATE; CHILDHOOD LEUKEMIA; GENE REARRANGEMENT; HETERODUPLEX ANALYSIS; HUMAN; LETTER; LEUKEMIA CELL; PROTEIN EXPRESSION; PROTEIN FOLDING; PROTEIN MICROARRAY; SIGNAL TRANSDUCTION;

EID: 84895452149     PISSN: None     EISSN: 20445385     Source Type: Journal    
DOI: 10.1038/bcj.2014.5     Document Type: Letter

References (23)

1. Pui CH, Carroll WL, Meshinchi S, Arceci RJ. Biology, risk stratification, and therapy of pediatric acute leukemias: an update. J Clin oncol 2011; 29: 551-565.
2. Barber KE, Harrison CJ, Broadfield ZJ, Stewart AR, Wright SL, Martineau M et al. Molecular cytogenetic characterization of TCF3 (E2A)/19p13.3 rearrangements in B-cell precursor acute lymphoblastic leukemia. Genes Chromosomes Cancer 2007; 46: 478-486.
3. Williams DL, Look AT, Melvin SL, Roberson PK, Dahl G, Flake T et al. New chromosomal translocations correlate with specific immunophenotypes of childhood acute lymphoblastic leukemia. Cell 1984; 36: 101-109.
4. Crist WM, Carroll AJ, Shuster JJ, Behm FG, Whitehead M, Vietti TJ et al. Poor prognosis of children with pre-B acute lymphoblastic leukemia is associated with the t(1;19)(q23;p13): a Pediatric Oncology Group study. Blood 1990; 76: 117-122.
5. Sakaguchi N, Melchers F. Lambda 5, a new light-chain-related locus selectively expressed in pre-B lymphocytes. Nature 1986; 324: 579-582.
6. Herzog S, Reth M, Jumaa H. Regulation of B-cell proliferation and differentiation by pre-B-cell receptor signalling. Nat Rev Immunol 2009; 9: 195-205.
7. Kwon K, Hutter C, Sun Q, Bilic I, Cobaleda C, Malin S et al. Instructive role of the transcription factor E2A in early B lymphopoiesis and germinal center B cell development. Immunity 2008; 28: 751-762.
8. Aspland SE, Bendall HH, Murre C. The role of E2A-PBX1 in leukemogenesis. Oncogene 2001; 20: 5708-5717.
9. van der Velden VH, van Dongen JJ. MRD detection in acute lymphoblastic leukemia patients using Ig/TCR gene rearrangements as targets for real-time quantitative PCR. Methods Mol Biol 2009; 538: 115-150.
10. Petricoin EF, Espina V, Araujo RP, Midura B, Yeung C, Wan X et al. Phosphoprotein pathway mapping: Akt/mammalian target of rapamycin activation is negatively associated with childhood rhabdomyosarcoma survival. Cancer Res 2007; 67: 3431-3440.
11. Advani RH, Buggy JJ, Sharman JP, Smith SM, Boyd TE, Grant B et al. Bruton tyrosine kinase inhibitor ibrutinib (PCI-32765) has significant activity in patients with relapsed/refractory B-cell malignancies. J Clin Oncol 2013; 31: 88-94.
12. Ponader S, Chen SS, Buggy JJ, Balakrishnan K, Gandhi V, Wierda WG et al. The Bruton tyrosine kinase inhibitor PCI-32765 thwarts chronic lymphocytic leukemia cell survival and tissue homing in vitro and in vivo. Blood 2012; 119: 1182-1189.
13. Rushworth SA, Bowles KM, Barrera LN, Murray MY, Zaitseva L, Macewan DJ. BTK inhibitor ibrutinib is cytotoxic to myeloma and potently enhances bortezomib and lenalidomide activities through NF-kappaB. Cell Signal 2012; 25: 106-114.
14. Den Boer ML, Harms DO, Pieters R, Kazemier KM, Göbel U, Körholz D et al. Patient stratification based on prednisolone-vincristine-asparaginase resistance profiles in children with acute lymphoblastic leukemia. J Clin Oncol 2003; 21: 3262-3268.
15. Herman SE, Gordon AL, Hertlein E, Ramanunni A, Zhang X, Jaglowski S et al. Bruton tyrosine kinase represents a promising therapeutic target for treatment of chronic lymphocytic leukemia and is effectively targeted by PCI-32765. Blood 2011; 117: 6287-6296.
16. Feldhahn N, Rio P, Soh BN, Liedtke S, Sprangers M, Klein F et al. Deficiency of Bruton's tyrosine kinase in B cell precursor leukemia cells. Proc Natl Acad Sci USA 2005; 102: 13266-13271.
17. Kim E, Koehrer S, Rosin NY, Thomas DA, Ravandi F, Kornblau SM et al. Activity of Bruton's tyrosine kinase (BTK) inhibitor ibrutinib (PCI-32765) in B-cell acute lymphoblastic leukemia (B-ALL). ASH Annual Meeting Abstracts 2012; 120: 2569.
18. Chang BY, Francesco M, De Rooij MF, Magadala P, Steggerda SM, Huang MM et al. Egress of CD19(+)CD5(+) cells into peripheral blood following treatment with the Bruton tyrosine kinase inhibitor ibrutinib in mantle cell lymphoma patients. Blood 2013; 122: 2412-2424.
19. de Rooij MF, Kuil A, Geest CR, Eldering E, Chang BY, Buggy JJ et al. The clinically active BTK inhibitor PCI-32765 targets B-cell receptor-and chemokine-controlled adhesion and migration in chronic lymphocytic leukemia. Blood 2012; 119: 2590-2594.
20. Ma S, Turetsky A, Trinh L, Lu R. IFN regulatory factor 4 and 8 promote Ig light chain kappa locus activation in pre-B cell development. J Immunol 2006; 177: 7898-7904.
21. Verma-Gaur J, Hauser J, Grundstrom T. Negative feedback regulation of antigen receptors through calmodulin inhibition of E2A. J Immunol 2012; 188: 6175-6183.
22. Moorman AV, Ensor HM, Richards SM, Chilton L, Schwab C, Kinsey SE et al. Prognostic effect of chromosomal abnormalities in childhood B-cell precursor acute lymphoblastic leukaemia: results from the UK Medical Research Council ALL97/99 randomised trial. Lancet Oncol 2010; 11: 429-438.
23. Byrd JC, Furman RR, Coutre SE, Flinn IW, Burger JA, Blum KA et al. Targeting BTK with ibrutinib in relapsed chronic lymphocytic leukemia. N Engl J Med 2013; 369: 32-42.